Fax: (312) 503-2777
General population norms for the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI)
Article first published online: 6 JUL 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 2, pages 429–437, 15 January 2013
How to Cite
Butt, Z., Peipert, J., Webster, K., Chen, C. and Cella, D. (2013), General population norms for the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI). Cancer, 119: 429–437. doi: 10.1002/cncr.27688
- Issue published online: 4 JAN 2013
- Article first published online: 6 JUL 2012
- Manuscript Accepted: 25 APR 2012
- Manuscript Revised: 7 APR 2012
- Manuscript Received: 31 JAN 2012
Vol. 119, Issue 9, 1762, Article first published online: 18 JAN 2013
- quality of life;
- renal cell cancer;
- general population;
- patient-reported outcome
Metastatic renal cell cancer is associated with poor long-term survival and has no cure. Traditional clinical endpoints are best supplemented by patient-reported outcomes designed to assess symptoms and function. Normative data was obtained on the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy–Kidney Symptom Index (NFKSI) to aid in score interpretation and planning of future trials.
General population data were obtained from 2000 respondents, who completed the 19-item NFKSI-19, as well the SF-36 (Short Form 36-item instrument) and the PROMIS-29 (29-item Patient Reported Outcomes Measurement Information System), both general health status measures. Basic demographic and self-reported comorbidity data were also collected.
The sample was 50% female, 85.7% caucasian, with an equal distribution across age bands from 18 years to 75 years and older. Most respondents (62.8%) had more than a high school education and reported an Eastern Cooperative Oncology Group performance status of normal activity without symptoms (63.4%). Score distributions on the NFKSI-19, its subscales, and individual items are summarized.
The NFKSI-19 and its subscales now have scores for the general US population, allowing comparability to generic questionnaires such as the SF-36 and PROMIS-29. These data can be used to guide treatment expectations and plan future comparative effectiveness research using the scales. Cancer 2013. © 2012 American Cancer Society.